Possible Role of Integrase Inhibitors in the Management of Untreated HIV-Infected Subjects in Intensive Care Units

Amedeo F Capetti1,2,3* and Giuliano Rizzardini4,5
1The Sexually Transmitted Diseases Unit of Luigi Sacco University Hospital, Milano, Italy
2School of Nursing, The Università Statale of Milano, Italy
3The Department of Infectious Diseases of Luigi Sacco University Hospital, South Africa
4The Whitewaterstrand University of Johannesburg, South Africa

Abstract
The introduction HIV integrase strand transfer inhibitors may help reduce the risk of acquiring the infection by the operators as well as developing complications by the patients, in case of admission of untreated HIV-1-infected subjects with potentially dangerous viremia, suppressing plasma HIV RNA concentrations by 10 folds every 3 days.

Keywords: Integrase inhibitors; Viral replication; Intensive care

Introduction
The World Health Organization (WHO) target to help end the Aquired Immuno Deficiency Syndrome (AIDS) epidemic is known as the "90-90-90" strategy [1]. This means that by the end of the year 2020, 90% of all people living with HIV will know their HIV status, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90% of this therapy will have viral suppression [1]. This means that Member States of the WHO should adopt a 'test and treat' strategy, which is often not the case at present. Therefore, the first step of the chain, to diagnose 90% of all HIV-infected subjects, is still far from being achieved and subjects presenting with AIDS symptoms or with less than 200 CD4+ T-cells/ mmc and uncontrolled viral replication, unaware of their condition, are still admitted in hospital, with proportions up to 47% of new diagnoses [2,3]. Other subjects receive diagnosis and know their infection, but either refuse to face it or get tired of medicines, visits, side effects and do not undergo follow-up nor take medications, at least until some disease brings them to hospital.

Risk for health care workers
Patients with uncontrolled viral replication potentially pose a threat to healthcare workers. An analysis performed by the US CDC as of December 31, 2013 has retrieved 58 cases of occupational HIV infection in health care workers and 150 possible transmissions, but only one confirmed case had been reported after 1999 [4]. However, in other countries and in other hospital settings rates may be higher, ranging from 2.4 to 24 cases per million medical procedures [5]. At least one needle stick injury occurs in 20% of anesthesiologists in a 3 month work period [6]. Wearing double gloves reduces contamination of the skin by body fluids from the patient to the surgical team [7], but again this is not the rule everywhere and in some parts of the world glove stocks may often be depleted. The risk of infection associated with the exposure of mucous membranes to the HIV-infected blood is 0.09% [8]. The risk of HIV transmission through body fluids such as urine, sputum, feces, vomits, nasal secretions, sweat, and tears is low or absent if they do not contain visible blood [9].

Post-exposure prophylaxis (PEP)
Once an injury has occurred to the health care worker, causing direct contamination with infected body fluids from a subject who has uncontrolled HIV-1 replication the health care worker should start as soon as possible, within 48 h, post-exposure prophylaxis, taking for 28 days a complete antiretroviral regimen and then checking HIV serostatus until the third or sixth month [10,11].

The Centers for Disease Control and Prevention recommend tenofovir disoproxil fumurate (TDF)/emtricitabine plus twice-daily raltegravir (RAL) or once-daily dolutegravir (DTG) [12]. However, when the source of contamination is a subject who has a history of documented selection of genotypic mutations, other specific regimens are used. The Italian guidelines, given the absence of evidence of occupational transmission of HIV-1 in subjects who have achieved undetectable viremia, do not suggest proposing PEP in such cases, although if required by the health worker who feels unsecure PEP may be offered [11]. The use of PEP however is not as frequent as it should, especially in high-risk settings, as some reports dramatically point out [13].

Risks for the patients
HIV infection per se is not a contraindication to surgery and since several years HIV-infected patients have even undergone transplants of solid organs and bone marrow [14,15] and even ExtraCorporeal Membrane Oxygenation (ECMO) [16]. However, 3-5 year survival rates in HIV-HCV co-infected subjects are lower as compared to the Hepatitis C Virus (HCV) monoinfected population, due to higher prevalence of severe infections. In a retrospective study of surgical outcomes in 332 HIV- infected and matched HIV-non infected patients from the Kaiser Permanente Medical Care Program showed that the HIV-infected patients had a higher incidence of postoperative pneumonia and higher 12-month mortality, although other operative outcomes were comparable for HIV-infected and HIV-non-infected patients. Viral suppression to fewer than 30,000 copies/mL reduced surgical complications [17]. A smaller study from South Africa on patients undergoing surgery or drainage of sepsis on the contrary has...

*Corresponding author: Amedeo F Capetti, Luigi Sacco University Hospital, Milano, Italy, Tel: 00393478436579; E-mail: amedeo.capetti@asst-fsb-sacco.it

Received December 06, 2017; Accepted January 02, 2018; Published January 10, 2018

Citation: Capetti AF, Rizzardini G (2018) Possible Role of Integrase Inhibitors in the Management of Untreated HIV-Infected Subjects in Intensive Care Units. J Perioper Crit Intensive Care Nurs 3: 141. doi:10.4172/2471-9870.10000141

Copyright: © 2018 Capetti AF, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
not found an impact on the surgical outcome by HIV serostatus nor CD4 T-cell counts [18]. However, in their cohort, drainage of infectious foci was more common in HIV-infected subjects.

Viral dynamics of HIV-1 in plasma after the initiation of an integrase inhibitor-containing regimen

The class of integrase strand transfer inhibitors (INSTI) at present comprises two unboosted compounds, DTG and RAL, and one that is included in a fixed dose combination (FDC) with a booster, elvitegravir (ELV). DTG and RAL have showed to cause an extremely rapid HIV-1 RNA decay in blood after treatment initiation, with a 1a slope reduction of about 1 log\textsubscript{10} HIV-1 RNA copies/mL every 3 days [19-21]. This means that after only 3 days of therapy a subject starting with 300,000 HIV-1 RNA copies/mL, a fairly high level of replication would drop below the threshold for increased risk of surgical complications, according to the Kaiser Permanente study. After 12 days of therapy the subject may have gone below the threshold of infectious risk to the health workers, according to the Italian Guidelines for PEP (Figure 1). ELV-related effect has been less studied and at different doses and with a different booster than the commercially available formulations in the Gilead Study 183-0101 [22], however a 1 log\textsubscript{10} decay has been observed in all subjects (n=40) at day 10 and a 2 log\textsubscript{10} decay in about 50%.

Factors that may reduce the efficacy of INSTIs: Adherence, drug-drug interactions and genotypic resistance

The main barriers to success for antiretroviral therapy are the patient's adherence, the presence of drug-drug interactions and the presence of resistance mutations.

In any ward adherence can be readily addressed by the health care workers with controlled daily administration.

DTG and RAL have minimal interactions with other drugs, while the ELV-containing FDC has a similar profile to protease inhibitors, boosting many companion drugs. DTG AUC decreases by 39% if co-administered with calcium carbonate and by 54% with ferrous fumarate in fasting conditions. Taking DTG 2 h before or 6 h after these minerals or with a high-fat meal effectively counters such effect [23]. The same effect results from the intake of antacids [24]. Concomitant administration of rifampicin, carbamazepine or tipranavir (TPV) reduces DTG C\textsubscript{min} by ≥ 75%, requiring doubling the dose of DTG [25]. Simultaneous administration of calcium carbonate antacid with RAL resulted in 32% reduction in C\textsubscript{min} and 55% reduction in AUC. Simultaneous administration of magnesium/aluminum with RAL resulted in 63% reduction in C\textsubscript{min} and 49% reduction in AUC. Administration of magnesium/aluminum either 2 h before or 2 hours after RAL resulted in 57% reduction in C\textsubscript{min} and 51-30% reduction in AUC, so the distance should be either 6 h before or 4 h later [26].

The possibility that the chosen antiretroviral regimen may be hampered by acquired resistant HIV-1 strains depends on the behaviour though which the patient had acquired the infection [27] and the rates of transmitted drug resistance in the HIV-infected population in that country.

The global prevalence of transmitted resistance to INSTIs is minimal with no demonstrated effect to date on DTG [28] and transmitted resistance to nucleoside analogues, the backbone of triple therapies, is particularly low in developing countries although and adequate surveillance system has still to be set [29]. DTG has a high genetic barrier, so that at least two mutations need to be transmitted to reduce its' efficacy, while RAL is more affected, and once a key mutation is present, tends to select accumulating mutations with progressive reduction in antiviral activity [30,31].

Practical implications of early treatment with an integrase inhibitor

The decision to treat immediately a patient with DTG or RAL must be preceded by the collection of plasma for HIV-1 quantitation and genotypic resistance testing, but the results can be acknowledged later. It takes generally two days for an RT-PCR HIV-1 RNA test to generate results and 10 days for a genotypic resistance test performed in urgency.

Figure 1: HIV-1 RNA decays dynamics in plasma after starting raltegravir or dolutegravir-based regimens with different initial viral concentrations.
Often a patient in an Intensive Care Unit is not able to swallow. In this case the preferred backbone would probably be chosen among abacavir, emtricitabine, lamivudine and tenofovir either using the liquid formulations, which are commercially available or crushing the tablets of the separate components or even the Truvada® tablet, which is allowed [32,33]. Also DTG tablets may be split into halves followed by immediate ingestion of both halves or crushed and added to a small amount of semi-solid food or liquid, all of which should be consumed immediately [34]. Raltegravir cannot be crushed; however it is also available as oral suspension which should be administered within 30 min of mixing.

In case of patients with uncontrolled HIV-1 replication whose viral strains harbours resistance mutations other compounds that may be given crushed or in liquid formulation include atazanavir, darunavir, didanosine, fosamprenavir, lopinavir/ritonavir, maraviroc, nevirapine, ritonavir, saquinavir, stavudine and zidovudine [34].

Conclusion

Since dolutegravir and raltegravir-based regimens offer the chance of rapidly controlling viral replication in untreated HIV-infected subjects, reducing the risk of acquiring infection through occupational exposure and improving the patient's response to surgery and ventilation, treatment should be started as soon as possible, having excluded the possibility of drug-drug interactions as well as the presence of previously documented HIV drug resistance.

Implications for Nursing

Rapidly abating HIV-1 replication renders daily care to HIV-infected subjects safer, however the level of awareness and prudence should not be lowered, as the possibility of an underlying drug-resistant strain cannot be 100% excluded and the patients' immune recovery takes longer time than viral suppression. HIV-infected subjects therefore have still to be considered more vulnerable, unless on stable suppressive therapy since several years.

Finally, for countries with endemic or imported HIV-2 infection, or in case of documented HIV-2 infection, it should be reminded that the data presented have been obtained on HIV-1, although this kind of drugs may also have some effect on HIV-2 [35].

References

1. UNAIDS Document 90-90-90-An ambitious treatment target to help end the AIDS epidemic.
2. Mocroft A (2014) Late presentation in HIV infection. European AIDS Congress, Rome, Italy.
3. Castelnuovo F (2017) Demographic, clinical and therapeutic features of HIV Late Presenters. J HIV and Ageing 2: 13-18.
4. https://www.cdc.gov/hiv/workplace/healthcareworkers.html
5. Prout J, Agarwal B (2005) Anaesthesia and critical care for patients with HIV infection. Continuing Education in Anaesthesia Critical Care and Pain 5: 153-156.
6. Avidan MS, Jones N, Poznaiak AL (2000) The implications of HIV for the anaesthetist and the intensivist. Anaesthesia 55: 344-354.
7. Matta H, Thompson AM, Rainey JB (1988) Does wearing two pairs of gloves protects operating theatre staff from skin contamination? Br Med J 297: 597-598.
8. Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V et al (2013) Updated U.S. public health service guidelines for the management of occupational exposures to HIV and recommendations for post-exposure prophylaxis. Infect Control Hosp Epidemiol 34: 875-892.
9. MMWR Morbidity and mortality report (1988) perspectives in disease prevention and health promotion update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other blood borne pathogens in health-care settings. Centers Dis Control Prev 37: 377-388.
10. Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, et al. (2016) Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA 318: 191-210.
11. (2016) Linee Guida Italiane sull’utilizzo dei farmaci antiretroviral e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1.
12. Centers for Disease Control and Prevention (2016) Updated guidelines for antiretroviral post-exposure prophylaxis after sexual, injection drug use or other non-occupational exposure to HIV, United States.
13. Malbye P, Kessy AT, Semali I (2017) Understanding the magnitude of occupational exposure to human immunodeficiency virus (HIV) and uptake of HIV post-exposure prophylaxis among healthcare workers in a rural district in Tanzania. J Hosp Infect 96: 276-280.
14. Harbell J, Terrault NA, Stock P (2013) Solid organ transplants in HIV-infected patients. Curr HIV AIDS Rep 10: 217-225.
15. Miro JM, Agüero F, Dluzos-Vále JC, Mueller NJ, Grossi P, et al. (2014) ESCMID Study Group of infection in compromised hosts. Infections in solid organ transplant HIV-infected patients. Clin Microbiol Infect. 7: 119-130.
16. Horikita S, Sanui M, Fujimoto Y, Lefor AK (2017) Successful repeat ECMO in a patient with AIDS and ARDS. BMJ Case Rep 2017: bcr2017219870.
17. Horberg MA, Hurley LB, Klein DB, Follansbee SE, Quesenberry C, et al. (2006) Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Arch Surg 141: 1238-1245.
18. Cacala SR, Mafana E, Thomson SR, Smith A (2006) Prevalence of HIV status and CD4 counts in a surgical cohort: Their relationship to clinical outcome. Ann R Coll Surg Engl 88: 46-51.
19. Laskey SB, Siliciano RF (2016) Quantitative evaluation of the antiretroviral efficacy of dolutegravir. JCI Insight 1: e88910.
20. Imaz A, Martinez-Picado J, Nibou J, Kashuba ADM, et al. (2016) HIV-1 RNA decay and dolutegravir concentrations in senes of patients starting a first antiretroviral regimen. J Infect Dis 214: 1512-1519.
21. Andrade A, Gued J, Rosenkranz SL, Lu D, Melors J, et al. (2015) Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct sub phases (1a and 1b). AIDS 29: 2419-2426.
22. DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, et al. (2006) Antiviral activity, pharmacokinetics and dose response of the HIV-1 integrase inhibitor GS-9137 (T2K-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 43: 1-5.
23. Song I, Borland J, Anya N, Wynne B, Piccalli S (2015) Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol 55: 490-496.
24. Cottrell ML, Hadzic T, Kashuba ADM (2013) Clinical pharmacokinetic, pharmacodynamics and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 52: 981-994.
25. Tivicyac Prescribing Information (2014) ViIV Healthcare.
26. (2014) Isetnress prescribing information and info from manufacturer. Merck & Co.
27. Frenz D, Van de Vijver D, Abecasis A, Albert J, Hamouda O, et al. (2014) Patterns of transmitted HIV drug resistance in Europe vary by risk group. PLoS One 9: e84495.
28. Doyle T, Dunn DT, Ceccherini-Silberstein F, De Mendoza C, Garcia F, et al. (2015) Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. J Antimicrob Chemother 70: 3080-3086.
29. Avila-Rios S, Sued O, Rheo SY, Shafter RW, Reyes-Teran G, et al. (2016) Surveillance of HIV transmitted drug resistance in Latin America and the Caribbean: A systematic review and meta-analysis. PLoS One 11: e0158560.
30. Anstett K, Brenner B, Mesplede T, Wainberg MA (2017) HIV drug resistance against strand transfer integrase inhibitors. Retrovirology 14: 36.
31. Baxter JD, Dunn D, White E, Sharma S, Geretti AM, et al. (2015) Global HIV-1 Transmitted drug resistance in the INSIGHT strategic timing of antiretroviral treatment trial. HIV Med. 16: 77-87.

32. European Medicines Agency (EMA) Ziagen: Procedural steps taken and scientific information after the authorization.

33. (2012) Email communication, Gilead Sciences.

34. Foisy M, Hughes C, Lamb S, Tseng A (2017) Oral antiretroviral administration: information on crushing and liquid drug formulations.

35. Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, et al. (2015) Dolutegravir in HIV-2-infected patients with resistant virus to first-line integrase inhibitors from the French Named Patient Program. Clin Infect Dis 60: 1521-1527.